AbbVie Inc. (ABBV)
NYSE • Healthcare
October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, AbbVie Inc. keeps $21 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 30
in 27 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
AbbVie beat consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, based on preliminary results reported July 31. Revenue rose 10.2% to about $17.0 billion from about $15.4 billion a year ago, while adjusted EPS came in at $3.65 versus the $3.61 estimate, about +1.1%, and net income increased to about $3.6 billion from $938 million a year ago. Gross profit reached about $14.4 billion with gross margin near 85%, and operating income was about $6.7 billion with operating margin around 40%, leaving profitability above revenue growth. Operating cash flow was $3.83 billion, the company repurchased roughly $1.5 billion of stock, and it paid about $3.1 billion in dividends. Next-period consensus calls for EPS of $3.87 on revenue of $17.32 billion.
Next report — what to expect
AbbVie Inc. (ABBV) reports next on October 30, 2026. Wall Street expects EPS of $3.86 on revenue of $17.31 billion. For trailing context, revenue grew +10.2% year over year last quarter. AbbVie has beaten EPS in 7 of 8 most recent quarters, so attention may center on whether it extends that pattern.
About AbbVie Inc.
AbbVie Inc. (NYSE: ABBV) is a healthcare company that discovers, develops, manufactures, and commercializes advanced medicines across immunology, oncology, neuroscience, eye care, and other therapeutic areas around the world. In Drug Manufacturers - General, AbbVie generated $61.2 billion of revenue in FY2025.
Today's Snapshot
ABBV closed 1.1% above yesterday's close, while its sector was flat. At the close, ABBV was within 2.4% of its 52-week high of 269.39. AbbVie won FDA approval for Juvmo, a new treatment.
Trading Volume
Above 10d avg 3.6M
3.8M
vs S&P 500 Today
Moderate Outperformance
+0.36%
Updated: October 2, 2026 at 20:07 UTC
ABBV Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$237.86 - $262.74Buy
- RSI (14)53.74Neutral
- Stochastic %K (14, 3, 3)37.09Neutral
- MACD Level (12, 26)1.64Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.